Familial Chylomicronemia Syndrome clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
The purpose of the study is to evaluate the efficacy of AKCEA-APOCIII-LRx as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
San Francisco, California and other locations